Abstract
To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.
Publication types
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / blood
-
Antibodies, Monoclonal / immunology*
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / blood
-
Antiviral Agents / immunology*
-
Double-Blind Method
-
Humans
-
Immunization Schedule*
-
Infant
-
Injections, Intramuscular
-
Palivizumab
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Respiratory Syncytial Virus Vaccines / administration & dosage
-
Respiratory Syncytial Virus Vaccines / standards*
-
Respiratory Syncytial Virus, Human / immunology*
-
Safety
-
Seasons
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents
-
Respiratory Syncytial Virus Vaccines
-
Palivizumab